552c7ae14ClaimNigeria immunized 23 million children against polio as part of eradication effortsAgreeDisagree
552c7ae14ClaimGavi, the Vaccine Alliance, has immunized over 1 billion children since 2000AgreeDisagree
552c7ae14ClaimIndia administered 8 million HPV vaccine doses in six months since its national campaign launchAgreeDisagree
552c7ae14ClaimThe Global Polio Eradication Initiative has reduced wild poliovirus cases by over 99% since 1988AgreeDisagree
552c7ae14ClaimGlobal immunization coordinates vaccination programs to protect populations from preventable diseases worldwideAgreeDisagree
552c7ae14ClaimPandemic-era disruptions caused the largest sustained decline in childhood vaccination in three decadesAgreeDisagree
552c7ae14ClaimGlobal immunization efforts should prioritize equity over efficiency — debated regarding the tension between maximizing total doses administered and targeting underserved populationsAgreeDisagree
552c7ae14ClaimBangladesh measles outbreaks killed over 1,000 children as vaccination gaps fueled the crisisAgreeDisagree
552c7ae14ClaimSatralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signalingAgreeDisagree
552c7ae14ClaimThyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidismAgreeDisagree
552c7ae14ClaimSatralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye diseaseAgreeDisagree
552c7ae14ClaimPrior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026AgreeDisagree
552c7ae14ClaimSatralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory conditionAgreeDisagree
552c7ae14ClaimSatralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare providerAgreeDisagree
552c7ae14ClaimAlthough satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2AgreeDisagree
552c7ae14ClaimOn October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye diseaseAgreeDisagree